Infectious Disease
RSSArticles
-
Clinical Briefs
In this section: managing diabetes; elective surgery; and nephrolithiasis patients.
-
Tisagenlecleucel Suspension (Kymriah)
Kymriah is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.
-
What Is the Ideal Target for Blood Pressure Control?
Researchers organized a study to address quality-of-life outcomes based on recent blood pressure recommendations.
-
Do Antibiotics Reduce Hormonal Contraceptive Effectiveness?
Researchers conducted a systematic review of studies that evaluated the effect of concomitant non-rifamycin antibiotic use on hormonal contraceptive effectiveness. Although data are limited, there was no evidence to support the existence of drug interactions.
-
Screening for Prostate Cancer May Offer Survival Benefits
Using a mathematical model to account for differences in implementation and baseline screening, researchers reassessed mortality data from two major studies and discovered that screening led to a 25-30% reduction of prostate cancer death in both.
-
Infectious Disease Alert Updates
Corporate Antibiotic Stewardship; Hypervirulence Meets Antibiotic Resistance — A Lethal Combination; Glue Masquerading as an Aortic Root Abscess; Molecular Diagnostic Coup
-
California and Coccidioidomycosis: Be Careful About the Air You Breathe
Cases of coccidioidomycosis significantly increased in 2016.
-
Delafloxacin (Baxdela®)
Delafloxacin is a new broad-spectrum fluoroquinolone that was approved by the U.S. Food and Drug Administration in June 2017 for acute bacterial skin and skin structure infections.
-
Fungal Endophthalmitis: Another Risk Associated With Intravenous Drug Use
A retrospective cohort study found that endogenous fungal endophthalmitis is associated with intravenous drug use and frequently results in poor visual outcomes despite appropriate surgical and antifungal therapy.
-
Rheumatic Heart Disease — The Global Situation
With advances in access to good medical care, the global burden of rheumatic heart disease is declining. However, there still is significant disease in resource-limited regions of the world.